<?xml version="1.0" encoding="UTF-8"?>
<boxed-text position="float" orientation="portrait">
 <caption>
  <title>Statement 7</title>
 </caption>
 <p>HBsAg-positive and/or HBV DNA-positive (i.e., those with chronic HBV infection) IBD patients who require moderateto-high risk immunosuppressive therapy should receive antiviral prophylaxis that starts before and continue for at least 6–12 months after the duration of immunosuppression (strong recommendation, with high level of evidence).</p>
 <p>· Level of agreement: strongly agree 87.5%, agree 12.5%, uncertain 0%, disagree 0%, strongly disagree 0%</p>
</boxed-text>
